ICYMI: Ibrutinib/rituximab combo improves CLL survivalJuly 31, 2019Leukemia, Myelodysplasia, Transplantation
BTK mutations linked to CLL progression on ibrutinibJuly 24, 2019Lymphoma & Plasma Cell DisordersLeukemia, Myelodysplasia, Transplantation
Ibrutinib-venetoclax found highly active in hard-to-treat CLLJuly 22, 2019Leukemia, Myelodysplasia, Transplantation
How to recognize pediatric leukemia cutisJuly 18, 2019Leukemia, Myelodysplasia, TransplantationNonmelanoma Skin Cancer
Ibrutinib tops chlorambucil against CLLJuly 10, 2019Leukemia, Myelodysplasia, TransplantationRare Diseases
ADMIRAL results solidify gilteritinib as new standard for FLT3-mutated AMLJune 27, 2019Leukemia, Myelodysplasia, Transplantation
Guadecitabine offers limited advantage over other standards for high-risk AMLJune 26, 2019Leukemia, Myelodysplasia, Transplantation
Rituximab and vemurafenib could challenge frontline chemotherapy for HCLJune 26, 2019Leukemia, Myelodysplasia, Transplantation
‘Robust antitumor immune responses’ observed in pediatric ALLJune 26, 2019PediatricsLeukemia, Myelodysplasia, Transplantation
Risk model could help predict VTE in acute leukemiaJune 26, 2019Patient & Survivor CareLeukemia, Myelodysplasia, Transplantation
AML variants before transplant signal need for aggressive therapyJune 25, 2019Leukemia, Myelodysplasia, Transplantation
For tough AML, half respond to selinexor plus chemotherapyJune 25, 2019Leukemia, Myelodysplasia, Transplantation
Hedgehog signaling offers prognostic, therapeutic potential in CLLJune 25, 2019Leukemia, Myelodysplasia, Transplantation
Bispecific CAR T-cell therapy yields complete responses in relapsed/refractory non-Hodgkin lymphomasJune 21, 2019ImmunotherapyLymphoma & Plasma Cell DisordersImmuno-oncologyLeukemia, Myelodysplasia, Transplantation
